Navigation Links
Wyeth and Progenics Receive Positive Opinion From European Committee for RELISTOR for the Treatment of Opioid-Induced Constipation in Advanced-Illness Patients
Date:4/24/2008

thout limitation, the inherent uncertainty of the timing and success of, and expense associated with, research, development, regulatory approval and commercialization of our products and pipeline products; government cost-containment initiatives; restrictions on third-party payments for our products; substantial competition in our industry, including from branded and generic products; emerging data on our products and pipeline products; the importance of strong performance from our principal products and our anticipated new product introductions; the highly regulated nature of our business; product liability, intellectual property and other litigation risks and environmental liabilities; uncertainty regarding our intellectual property rights and those of others; difficulties associated with, and regulatory compliance with respect to, manufacturing of our products; risks associated with our strategic relationships; economic conditions including interest and currency exchange rate fluctuations; changes in generally accepted accounting principles; trade buying patterns; the impact of legislation and regulatory compliance; risks and uncertainties associated with global operations and sales; and other risks and uncertainties, including those detailed from time to time in our periodic reports filed with the Securities and Exchange Commission, including our current reports on Form 8-K, quarterly reports on Form 10-Q and annual report on Form 10-K, particularly the discussion under the caption "Item 1A, RISK FACTORS" in our Annual Report on Form 10-K for the year ended December 31, 2007, which was filed with the Securities and Exchange Commission on February 29, 2008. The forward-looking statements in this press release are qualified by these risk factors. We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

Progenics Pharmaceuticals, Inc., of Tarrytown, NY, is a biopharma
'/>"/>

SOURCE Wyeth Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Wyeth to Present at the Lehman Brothers Eleventh Annual Global Healthcare Conference
2. Wyeth Sets Webcast And Conference Call For 2008 First Quarter Earnings
3. Wyeth To Appeal Arkansas Hormone Therapy Trial Verdicts
4. Wyeth Pharmaceuticals Ends Collaboration Agreements with Solvay Pharmaceuticals for Bifeprunox and Other Compounds
5. Wyeth Announces Executive Change in Finance Organization
6. Wyeth Announces Election of Timothy P. Cost as Senior Vice President, Corporate Affairs
7. Wyeth to Present at the Merrill Lynch 2008 Global Pharmaceutical, Biotechnology and Medical Device Conference
8. Wyeth Reports Earnings Results for the 2007 Fourth Quarter and Full Year
9. Wyeth Consumer Healthcare Supports U.S. Food and Drug Administration Decision for Over-the-Counter Cough and Cold Medications in Children under Two Years of Age
10. Wyeth Will Pursue Claim for Damages Resulting From Teva Pharmaceuticals Launch of Generic Pantoprazole in Violation of PROTONIX Patent
11. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014 Sigma-Aldrich ... that the waiting period under the Hart-Scott-Rodino Antitrust ... acquisition expired on December 22, 2014, thereby completing ... requirement for the acquisition of the Company by ... antitrust clearance satisfies another condition to closing the ...
(Date:12/24/2014)... and NEW YORK , Dec. ... its open-label pilot study of mazindol in children with ... and Therapy in December 2014 . ... in children with attention deficit/hyperactivity disorder" ( Konofal et ... 2014 Dec 1;8:2321-2332. eCollection 2014 ) shows that ...
(Date:12/22/2014)... ROCKVILLE, Md. , Dec. 22, 2014 ... MKT: SYN), a developer of pathogen-specific therapies ... focus on protecting the microbiome, today announced ... a Phase 1a clinical trial of SYN-004, ... the prevention of Clostridium difficile (C. ...
(Date:12/22/2014)... CHAPEL HILL, N.C. , Dec. 22, 2014 ... ALNE) today announced that it has signed a ... biotechnology company that has developed and patented a ... and medical diagnostics products that enable rapid on-site ... and alcohol use/abuse and health issues in an ...
Breaking Biology Technology:Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5ALNE Announces Intention To Acquire BioTechPharma 2
... PAT and QbD remains a field that still lacks ... Pharma IQ across the PAT and QbD community it was  found ... not implementing PAT/QbD was due to a lack of personnel with ... opens its doors to industry specialists from the PAT and QbD ...
... Germany, October 11, 2011 joimax® opened ... patronage of the German Academy for Neurosurgery (GANS) and ... Neurosurgery at the "Städtisches Klinikum" in Karlsruhe, Prof. Dr. ... place in Karlsruhe, South Germany, October 5 to 8. ...
... Oct. 11, 2011 STAAR Surgical Company (NASDAQ: STAA ) ... quarter ended September 30, 2011 on Monday, October 24, 2011 ... will host a conference call on Monday, October 24, 2011 ... to discuss the Company,s third quarter results and recent corporate ...
Cached Biology Technology:Establishing the Correct QbD Strategies and Tools Early in the Development Process is Key to Ensuring we Have Robust Quality Products Downstream 2joimax® Inspires Thai-German Neurosurgery Congress Participants for TESSYS® 2joimax® Inspires Thai-German Neurosurgery Congress Participants for TESSYS® 3STAAR Surgical Announces Third Quarter 2011 Results Release Date and Conference Call 2
(Date:12/17/2014)... 15, 2014 Research and Markets ... the "Samsung Galaxy S5 - Home Button ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... sensing technology than the iPhone 5S, Samsung introduces ... its product. The Galaxy S5 home ...
(Date:12/17/2014)... 16, 2014 Valencell, a leader in performance ... technology to industry leaders such as Intel, Jabra, Atlas, ... biometric wearable products. These products will be showcased at ... Las Vegas . "Our partners ... and robust – with the clinical data to back ...
(Date:12/15/2014)... Dec. 12, 2014 Research and Markets ... of the "Global Facial Recognition Market 2015-2019" ... http://photos.prnewswire.com/prnh/20130307/600769 Facial recognition ... individuals. Facial recognition system measures the overall facial ... edges, mouth, and the distance between eyes. Facial ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... Dec. 17, 2012 The University of Houston (UH) ... thanks to a computer hardware donation from Total, a ... nodes that will occupy four racks of space. ... computing resources," said Jaspal Subhlok, chairman of UH,s department ...
... December 2012)New research released today, on the eve of an ... agencies and investors for a growing spate of violent clashes ... of resources from the rural poor to investors is underway, ... Top global experts at the meeting noted as well that ...
... up on snack foods may increase cancer risk in ... cancers. Published early online in CANCER , a ... suggests that an eating pattern low in snack foods ... syndromelower their risk. Lynch syndrome is an inherited ...
Cached Biology News:Total donates high-speed computer cluster to UH 2New research predicts rising trend in India's Violent Land Conflicts; 130 districts struggle 2New research predicts rising trend in India's Violent Land Conflicts; 130 districts struggle 3New research predicts rising trend in India's Violent Land Conflicts; 130 districts struggle 4Snack attack: Eating unhealthy snack foods may affect cancer risk in patients with Lynch syndrome 2
...
...
SphingoStripsTM contain fifteen different biologically active, nitrocellulose-immobilized lipids at 100 pmol per spot, which can be assayed for protein binding and specificity using a simple blot ove...
The Discovery Series PDQuest 2-D analysis software is used for imaging, analyzing, and databasing two-dimensional electrophoretic gels. The version upgrade allows upgrade of an established version of...
Biology Products: